AZD4604 free base · Synonyms: Londamocitinib | JAK1-IN-7

AZD4604 is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.

For research use only. Not for human or veterinary use.

Target JAK

Research area Inflammation/Immunology

Purity >98% Stock Inquire

Data Sheet SDS COA

AZD4604 structure

CAS No.: 2241039-81-4

Download structure (.mol)

Pack sizes & pricing

Size	Price	SKU	Stock
25 mg	USD 420.00	BP-01993-25mg	In stock	Get quote
50 mg	USD 650.00	BP-01993-50mg	In stock	Get quote
100 mg	USD 942.00	BP-01993-100mg	In stock	Get quote
250 mg	USD 1,360.00	BP-01993-250mg	In stock	Get quote
500 mg	Inquire	BP-01993-500mg	In stock	Inquire
1 g	Inquire	BP-01993-1g	In stock	Inquire

Need another size or custom synthesis? Request a quote.

Description

AZD4604 is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.

Biological activity

In Vitro Londamocitinib inhibits the phosphorylation of STAT6 in U937 cells induced by IL-4 or IL-13 (IC50 are 24 and 34 nM, respectively). In Vivo Londamocitinib (1 mg/kg, intravenous injection, single dose) can reduce the phosphorylation of STAT3 and STAT5 in the lung of obumin-induced asthmatic rats, inhibit pulmonary eosinophilia, and reduce advanced asthma response in the same model.

Identifiers

SMILES: COC[C@@H](N1CCN(CC1)C)C(NC2=C3C(C(C4=NC(NC5=C(C(S(C)(=O)=O)=CC=C5)F)=NC=C4F)=CN3)=CC=C2)=O
InChIKey: JNUZADQZHYFJGW-JOCHJYFZSA-N

Specifications

MW (average): 599.6520
Formula: C₂₈H₃₁F₂N₇O₄S
CAS No.: 2241039-81-4
Physical state: Solid
Color: White to off-white
Shipping: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage: Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 71.43 mg/mL

Documents

References

[1]. NILSSON, Karl, Magnus, et al. Jak1 selective inhibitors. WO2018134213A1.

[2]. Nilsson M, et al. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. J Med Chem. 2023 Oct 12;66(19):13400-13415.

[3]. Nilsson M, et al. Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des Devel Ther. 2022 Aug 31;16:2901-2917.

Same target

Search JAK

Same research area

Search Inflammation/Immunology